BHCM
COGT icon

Brevan Howard Capital Management’s Cogent Biosciences COGT Stock Holding History

Brevan Howard Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67M Buy
68,945
+63,744
+1,226% +$2.23M 0.02% 599
2026
Q1 		$200K Buy
+5,201
New +$192K ﹤0.01% 1895
2025
Q3 		– Sell
-41,481
Closed -$298K – 1981
2025
Q2 		$298K Buy
+41,481
New +$230K ﹤0.01% 1555
2024
Q3 		– Sell
-22,559
Closed -$190K – 1180
2024
Q2 		$190K Buy
+22,559
New +$171K ﹤0.01% 903

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brevan Howard Capital Management's COGT Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Cogent Biosciences (COGT) stake by 1,226% in Q2 2026, buying an estimated $2.23M and bringing the position to 68,945 shares worth $2.67M. The position accounts for 0.02% of the portfolio, ranked #599.

Brevan Howard Capital Management first reported a position in COGT in Q2 2024 and has held it in 4 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Brevan Howard Capital Management held 68,945 shares of Cogent Biosciences worth $2.67M as of Q2 2026.
  • Brevan Howard Capital Management bought 63,744 Cogent Biosciences shares in Q2 2026, an estimated $2.23M.
  • Cogent Biosciences made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #599 holding.
  • Brevan Howard Capital Management first reported a position in Cogent Biosciences in Q2 2024 and has held it in 4 quarters since.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.